5DT Stock Overview
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Entera Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$2.58 |
| 52 Week Low | US$1.29 |
| Beta | 1.52 |
| 1 Month Change | -1.30% |
| 3 Month Change | -17.13% |
| 1 Year Change | -22.50% |
| 3 Year Change | -17.52% |
| 5 Year Change | n/a |
| Change since IPO | -62.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5DT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.3% | 1.7% |
| 1Y | -22.5% | -13.7% | 16.5% |
Return vs Industry: 5DT underperformed the German Biotechs industry which returned -13.7% over the past year.
Return vs Market: 5DT underperformed the German Market which returned 16.5% over the past year.
Price Volatility
| 5DT volatility | |
|---|---|
| 5DT Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 5DT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5DT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Miranda Toledano | www.enterabio.com |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures.
Entera Bio Ltd. Fundamentals Summary
| 5DT fundamental statistics | |
|---|---|
| Market cap | €76.93m |
| Earnings (TTM) | -€8.94m |
| Revenue (TTM) | €197.60k |
Is 5DT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5DT income statement (TTM) | |
|---|---|
| Revenue | US$223.00k |
| Cost of Revenue | US$214.00k |
| Gross Profit | US$9.00k |
| Other Expenses | US$10.10m |
| Earnings | -US$10.09m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 4.04% |
| Net Profit Margin | -4,525.11% |
| Debt/Equity Ratio | 0% |
How did 5DT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 02:18 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| null null | CG Capital |
| Raghuram Selvaraju | H.C. Wainwright & Co. |